Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables, has launched Glydo (lidocaine HCI jelly USP, 2%), Sagent's new branded drug offering.
Glydo is a topical urological anaesthetic lubricant available in prefilled, ready-to-use, disposable plastic syringes in two unique sizes—6 mL and 11 mL. Glydo syringes are individually packaged and sterilized, allowing Glydo to be used during surgical procedures while maintaining the integrity of the sterile field.
According to IMS, for the 12 months ending July 2014, the US market for lidocaine HCI jelly, 2% is approximated at $30 million. As with all products in Sagent's portfolio, Glydo features the company's PreventIV MeasuresSM packaging and labelling, designed to help reduce medication errors.
"Sagent is proud to offer Glydo, a sterile urological anaesthetic lubricant, to the US market. Glydo is provided in a novel prefilled syringe, designed by urologists specifically for the urology market, which is used in over 40 countries, with more than 500 million applications," said Jeffrey M Yordon, chief executive officer and chairman of the board.
Glydo (lidocaine HCI jelly USP, 2%) is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anaesthetic lubricant for endotracheal intubation (oral and nasal).